The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), is seeking innovative ideas and strategies to develop a single-dose vaccine for pandemic influenza. This Request for Information (RFI) is designed to gather valuable insights from biopharmaceutical companies, research institutions, and vaccine development experts to facilitate the creation of a vaccine that offers durable immunity with a single administration.
Through RFI No. 24-PRIZE-RFI-001, BARDA aims to identify feasible approaches and technologies that could significantly enhance national and global preparedness against potential influenza pandemics. The initiative seeks to streamline vaccine deployment and immunization practices during influenza outbreaks, reducing logistical burdens and improving rapid response capabilities. “This RFI from BARDA marks a key step in enhancing pandemic readiness through single-dose vaccines, emphasizing the urgent need for innovative vaccine delivery and public health strategies to bolster our defenses against future influenza pandemics,” stated EverGlade Managing Consultant, Stephen Richardson.
Focus on Novel Antigen Designs, Vaccine Formulations, and Delivery Platforms
Interested parties are invited to submit their responses, which should focus on novel antigen designs, vaccine formulations (including adjuvants), and delivery platforms that could be adapted to pandemic influenza strains. Respondents are also encouraged to address potential challenges in vaccine development, such as scalability, manufacturing, and regulatory hurdles.
“The RFI release demonstrates BARDA’s commitment to public health innovation. By exploring single-dose vaccine development, they’re addressing gaps in health security and preparing for more effective responses to infectious diseases,” stated EverGlade Consulting Founder, Eric Jia-Sobota.
RFI Response Deadline
Submissions to this RFI will help shape the future of influenza vaccine strategies and may inform the design of subsequent funding opportunities or prize competitions aimed at accelerating vaccine development. Responses should be concise, formatted as per the guidelines detailed in the RFI document, and submitted by the deadline of 4:59 p.m. EDT on Monday, August 5, 2024, to [email protected].
If your company has considered applying for BARDA funding, your federal funding journey starts here.
For additional information about EverGlade Consulting, reach out to: [email protected]
